Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN81,2181,24-1,65
Msft1,77
Nokia3,8013,903-1,67
IBM-1,39
Mercedes-Benz Group AG51,5351,55-0,71
PFE-3,98
13.09.2025 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 12.09.2025 17:35:29
Genus (GENS.L, London)
Poslední obchod Změna (%) Změna (GBP) Objem obchodů (GBP)
26,15 -3,51 -0,95 1 669 040
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace:
Popis společnosti
Obecné informace
Název společnostiGenus plc
TickerGNS
Kmenové akcie:Ordinary Shares
RICGNS.L
ISINGB0002074580
Poslední známé roční výsledky30.06.2025
Poslední známé čtvrtletní výsledky30.06.2025
Počet zaměstnanců k 30.06.2024 3 439
Akcie v oběhu k 31.07.2025 66 037 454
MěnaGBP
Kontaktní informace
UliceMatrix House, Basing View
MěstoBASINGSTOKE
PSČRG21 4DZ
ZeměUnited Kingdom
Kontatní osobaAnand Date
Funkce kontaktní osobyInvestors Relations
Telefon441 256 347 100
Fax441256477385
Kontatní telefon447 815 676 011

Business Summary: Genus plc is a United Kingdom-based global animal genetics company. The Company is advancing animal breeding and genetic improvement by applying biotechnology and selling added value products to livestock farming and food producers. It focuses on the dairy, beef and pork food production sectors, through two businesses: ABS (bovine genetics) and PIC (porcine genetics). Its segments include Genus PIC, Genus ABS and Genus Research and Development. Its bovine genetics business sells dairy and beef bull semen and embryos from its superior cattle, which are sold to farmers to breed their cows through artificial insemination. Its porcine genetics business sells genetically superior breeding pigs and semen to farmers, so they can breed commercial pigs with desirable characteristics for pork production. Its porcine and bovine divisions operate under the brand names PIC and ABS. It operates in 30 countries, across six continents, and reaches a further 50 markets through distribution partners.
Financial Summary: BRIEF: For the fiscal year ended 30 June 2025, Genus plc revenues increased 1% to L672.8M. Net income increased from L7.9M to L19.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Other Non Rec. I/E - Non Business decrease of 43% to L13.3M (expense), Litigation and damages decrease of 91% to L900K (expense), Operating expense decrease of 1% to L593.2M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSSupport Activities for Animal Production
NAICS2007Research and Development in Biotechnology
NAICS2007Support Activities for Animal Production
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Support Activities for Animal Production
SICCommercial Physical Research
SICLivestock Svcs, Exc. Veterinary



  • Poslední aktualizace:
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Executive DirectorJorgen Kokke5501.07.202302.05.2023
Chief Financial Officer, Executive DirectorAndy Russell-01.08.202501.08.2025
Chief Operating OfficerMatt Culbertson-
Chief Human Resources OfficerAngelle Rosata-01.07.2017
Chief Scientific Officer and Head of Research and DevelopmentElena Rice-
Group General Counsel and Company SecretaryDan Hartley-09.06.201409.06.2014
Chief Operating Officer of Genus ABSJim Low-01.01.2024
Regional Director - ABS EMEAJerry Thompson-01.07.2012